Summary
Celiac disease is an immune-mediated enteropathy triggered by dietary gluten in genetically susceptible children, and the pediatric diagnostic pathway now allows a confirmed diagnosis without intestinal biopsy in selected children [1]. The no-biopsy pathway rests on high-titer serology confirmed on a second sample, and it applies only when its criteria are met in full [1].
- Serologic testing begins with IgA anti-tissue transglutaminase antibody together with a total IgA level to detect the IgA deficiency that would make the primary test unreliable [1].
- The child must be consuming gluten at the time of testing. A gluten-free diet started before evaluation normalizes serology and mucosa and invalidates the workup [1].
- Biopsy can be omitted when anti-tissue transglutaminase IgA is at or above ten times the upper limit of normal, endomysial antibody is positive on a separate blood sample, and the diagnosis is made by a pediatric gastroenterologist [1].
- Children who do not meet the no-biopsy criteria proceed to duodenal biopsy for histologic confirmation [1].
Caution. Do not start a gluten-free diet before the diagnosis is complete. Removing gluten empirically to see if symptoms improve is the single most common way a diagnosis is lost, because it makes both serology and histology unreliable and commits the child to either an unconfirmed lifelong diet or a gluten challenge later [1].
Diagnosis
The evaluation is serologic first, and the antibody titer determines whether biopsy can be avoided [1].
| Step |
Test |
Purpose |
| Initial |
tTG-IgA plus total IgA |
Primary screen; total IgA detects deficiency [1] |
| If IgA deficient |
IgG-based testing (e.g., DGP-IgG) |
Valid alternative when IgA is low [1] |
| Confirmation |
Endomysial antibody on second sample |
Required for the no-biopsy route [1] |
| If criteria unmet |
Duodenal biopsy |
Histologic confirmation [1] |
The structured serologic pathway, including the antibody thresholds and the HLA and symptom considerations, is the framework that determines each child's route.
Work through the serologic criteria in ESPGHAN Celiac →
HLA-DQ2 and DQ8 typing has a specific and limited role. Its value is in its negative predictive power, because the absence of both alleles makes celiac disease very unlikely, whereas their presence is common in the general population and does not confirm the diagnosis [1].
Management and context
Treatment is a strict lifelong gluten-free diet, and confirming the diagnosis rigorously before starting it is what justifies that lasting commitment [1]. Once the diagnosis is established, serology is used to monitor adherence, with falling antibody titers tracking mucosal healing over months [1].
The pediatric no-biopsy pathway is more permissive than the approach used in adults, where guidelines continue to rely on duodenal biopsy for most diagnoses [2][3]. That difference reflects the strong correlation between high-titer serology and histology in children and the desire to avoid endoscopy and anesthesia when the result is not in doubt [1]. Applying the adult expectation of universal biopsy to a child who fully meets the no-biopsy criteria adds risk without adding certainty [1].
Screen the higher-risk groups even when they are asymptomatic, including children with type 1 diabetes, autoimmune thyroid disease, Down syndrome, Turner syndrome, and first-degree relatives of affected patients, because celiac disease in these groups is frequently silent [1].
References
- Husby S, Koletzko S, Korponay-Szabo I, et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition guidelines for diagnosing coeliac disease 2020. J Pediatr Gastroenterol Nutr. 2020;70(1):141-156. doi:10.1097/MPG.0000000000002497
- Husby S, Koletzko S, Korponay-Szabo IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54(1):136-160. doi:10.1097/mpg.0b013e31821a23d0
- Ludvigsson JF, Bai JC, Biagi F, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut. 2014;63(8):1210-1228. doi:10.1136/gutjnl-2013-306578